Granules India Ltd (GRANULES) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Granules India Ltd on NSE and BSE, with an AI summary of each filing.
Audio recording of the Earnings Conference call for Q2 and the half -year of FY27
Audio / Video · 03 Nov 2026, 3:01 am
Granules India Releases Audio Recording for Q2 and H1 FY27 Earnings Call Granules India Limited announced on 2nd Nov'26 that the audio recording for its Q2 and H1 FY27 earnings conference call has been made publicly available. In compliance with Regulation 46 of SEBI LODR Regulations, 2015, the recording has been uploaded to the company's official investor relations portal following the scheduled call previously intimated on 26th Oct'26.
Monitoring Agency Report for the quarter ended on September 30, 2026
Others (Uncategorized) · 02 Nov 2026, 11:57 pm
Granules India Preferential Issue Monitoring Agency Report for Sep'26 Quarter India Ratings & Research reported zero deviation in Granules India's preferential issue proceeds utilization for the quarter ended 30th Sep'26. Out of the INR 1,762.50 Cr total issue size, the company received INR 1,761.75 Cr, including INR 1,096.13 Cr realized during the quarter upon converting 2,49,82,906 warrants into equity. Total utilization reached INR 696.86 Cr, with INR 64.07 Cr deployed during the quarter across working capital, capex, and general corporate purposes. The unutilized balance of INR 1,064.89 Cr remains parked in bank fixed deposits and operational accounts.
Investor Presentation to Analysts/Investors
Investor Presentation · 02 Nov 2026, 10:36 pm
Granules India Reports Strong Q2 FY27 Results with 39% YoY PAT Growth Granules India posted revenue of ₹15,600 Mn (+20% YoY, +6% QoQ) in Q2 FY27, crossing ₹15,000 Mn quarterly revenue. EBITDA reached ₹3,376 Mn (+21% YoY, flat QoQ) with margins at 21.6%, while PAT surged 39% YoY (+1% QoQ) to ₹1,818 Mn. Gross margin contracted 134 bps YoY to 64.4% due to higher input and logistics costs. Balance warrant proceeds shifted the firm to net cash of ₹8,280 Mn (Net Debt/EBITDA at -0.61x). Complex Generics revenue grew 38% YoY, supported by 3 potential sole first-to-file ANDA filings.
Press Release
Press Release · 02 Nov 2026, 10:31 pm
Granules India Reports Strong Q2FY27 Results with 39% YoY PAT Growth Granules India reported Q2FY27 revenue of INR 15,600 Mn, up 20% YoY (6% QoQ), with EBITDA rising 21% YoY to INR 3,376 Mn (22% margin) and PAT surging 39% YoY to INR 1,818 Mn. Finished dosages contributed 73% of revenue, followed by API at 13%, PFI at 10%, and Peptides CDMO at 3%. Geographically, North America accounted for 72% and Europe 16%. ROCE stood at 17.6%. Aided by warrant proceeds, net cash reached INR 8,280 Mn versus net debt of INR 1,012 Mn in Q1FY27.
Unaudited financial results for the second quarter and half year ended on September 30,2026
Financial Result · 02 Nov 2026, 10:29 pm
Outcome of the Board meeting dated November 02, 2026.
Outcome · 02 Nov 2026, 10:20 pm
Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 02 Nov 2026, 10:18 pm
Granules India Reports Strong Q2 FY27 Consolidated Results Amid Warrant Conversion Granules India reported consolidated revenue from operations of Rs 15,599.74 Mn for the quarter ended 30th Sep'26, up 20.3% YoY from Rs 12,969.88 Mn and 5.6% QoQ. Consolidated net profit reached Rs 1,818.37 Mn, up 39.2% YoY, with diluted EPS at Rs 7.03. During the period, 24,982,906 convertible warrants were converted into equity shares, raising Rs 10,961.25 Mn. Additionally, USFDA completed an inspection at its Gagillapur facility in Oct'26 with a Form 483, posing no data integrity issues or impact on manufacturing and distribution.
Press Release
Press Release · 31 Oct 2026, 4:17 am
Granules India Gagillapur Facility Receives Eleven USFDA Form 483 Observations The USFDA concluded a cGMP inspection at Granules India's Gagillapur finished dosage facility on 30th Oct'26, issuing a Form 483 with 11 observations. This marked the site's first inspection since receiving a Warning Letter on 26th Feb'25. Observations relate to investigations, change control, equipment qualification, visual inspection, and documentation practices, with zero issues concerning data integrity or cross-contamination. Current manufacturing and distribution remain unaffected, and the company plans to submit its comprehensive response within the mandated 15 business days.
Intimation of Schedule of the Earnings Conference call for Q2 and Half year of FY27.
Intimation · 02 Nov 2026, 6:00 pm
Granules India Schedules Q2 and H1 FY27 Earnings Call for November 2026 Granules India Limited has scheduled its analyst and investor earnings conference call for Q2 and H1 FY27 on 2nd Nov'26 at 06:00 PM IST. The management team, including Chairman & MD Dr. Krishna Prasad Chigurupati, Executive Director Priyanka Chigurupati, CFO Mukesh Surana, CTO Dr. P.V. Srinivas, and Senn Tides India CEO Sanjay Kumar, will discuss the company's financial performance and business updates.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mrs Chigurupati Uma Devi, Mrs Priyanka Chigurupati, ....
Acquisition/ Disposal of Shares · 24 Oct 2026, 5:13 pm
Granules India Promoters Receive Preferential Allotment of 2.50 Crore Convertible Warrants Granules India Limited allotted 2,49,82,906 convertible warrants on a preferential basis to promoter group members on 23rd Feb'26 at ₹585 per warrant, receiving an upfront payment of 25% (₹146.25 each). Following this allotment, the combined holding of the acquirers and persons acting in concert stands at 38.02% of voting capital and 43.69% on a fully diluted equity base of 27.28 crore shares, representing a 9.16% diluted stake addition upon full warrant conversion within 18 months.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mrs Chigurupati Uma Devi, Mrs Priyanka Chigurupati, ....
Acquisition/ Disposal of Shares · 24 Oct 2026, 5:12 pm
Granules India Promoter Group Acquires 9.16% Stake via Warrant Conversion Granules India Limited allotted 2,49,82,906 equity shares on 16th Sep'26 to promoter group members upon conversion of preferential warrants at an issue price of ₹585 per warrant (balance ₹438.75 paid). This converted a 9.16% equity stake, primarily to Mrs. Chigurupati Uma Devi (2,48,80,342 shares). Consequently, aggregate promoter and PAC voting shareholding increased from 31.08% (7,70,03,525 shares) to 37.39% (10,19,86,431 shares). Total post-allotment equity share capital expanded to ₹27.28 crore (27,27,79,827 shares of ₹1 each), leaving only 17,094 non-promoter warrants outstanding.
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Krishna Prasad Chigurupati & PACs
Acquisition/ Disposal of Shares · 24 Oct 2026, 5:09 pm
Granules India Promoter Dr Krishna Prasad Chigurupati Sells 6.94% Stake Granules India promoter Dr Krishna Prasad Chigurupati sold 1.72 crore equity shares (6.94% of voting capital; 6.31% diluted) on 11th Sep'26 via NSE through block deals (1.33 crore shares) and normal market trades (39.05 lakh shares). Post-transaction, his direct holding decreased from 31.00% (7.68 crore shares) to 24.06% (5.96 crore shares). Total promoter group voting rights declined from 38.02% to 31.08% (28.23% diluted equity share capital). Promoter group warrant holdings remain unchanged at 2.50 crore units (9.16% diluted).
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
GRANULES INDIA LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
Granules India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve the unaudited financial results ....
Intimation · 02 Nov 2026, 5:30 am
Granules India Schedules Board Meeting on 2nd Nov'26 to Consider Q2 Results Granules India Limited has scheduled a meeting of its Board of Directors on 2nd Nov'26 to consider and approve the unaudited financial results for the second quarter and half-year ended 30th Sep'26. In accordance with insider trading regulations, the company's trading window remains closed until 4th Nov'26.
Incorporation of Wholly Owned Foreign Subsidiary
Others (Uncategorized) · 23 Oct 2026, 8:53 pm
Granules India Incorporates Wholly Owned Subsidiary in Mexico Granules India Limited incorporated a wholly owned foreign subsidiary, Triton Farmaceutica, S.A. de C.V., in Mexico on 22nd Oct'26. The new entity has an authorized share capital of 4,50,000 shares at MXN 10.00 each, with Granules holding 100% ownership. Triton Farmaceutica is established to manufacture, promote, sell, and distribute pharmaceutical and related products across Mexico. The promoter and promoter group hold no interest in the newly formed entity, which has yet to commence business operations.
Press Release
Press Release · 07 Oct 2026, 6:10 pm
Granules India Submits Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets Granules India Limited announced on 7th Oct'26 that it has submitted a Paragraph IV certification with its Abbreviated New Drug Application (ANDA) for generic Ruxolitinib Extended-Release Tablets to the US FDA. Based on filing status and timing, the company believes it is eligible for first-to-file status, which, upon FDA confirmation and statutory approvals, could provide 180 days of generic drug marketing exclusivity under US law. The ANDA, exclusivity status, and commercialization prospects remain under regulatory review.
Transcript of the Webinar held on September 29,2026
Transcript · 06 Oct 2026, 11:00 pm
Granules India Outlines Long-Term Growth Engines and ₹2,000 Crore Expansion Plan Granules India plans to invest ₹2,000 crore in organic capex over the next 3–4 years, targeting complex generics, oncology, US operations, and peptide CDMO. Peptide CDMO entity Senn Tides targets $50m revenue in three years and over $100m in five years. Complex generics contribution reached 33% of FY26 revenue, supported by a strong first-to-file pipeline. R&D spending expanded to 6% of revenue in Q1 FY27, while ROCE rose YoY to 18%. Warrants proceeds received in Sep'26 elevated the company to a consolidated net cash position.
Incorporation of a Wholly owned foreign Subsidiary
Others (Uncategorized) · 03 Oct 2026, 2:04 am
Granules India Incorporates Wholly Owned Subsidiary in Brazil Granules India Limited announced on 1st Oct'26 that it has incorporated a wholly owned foreign subsidiary, Triton Farmaceutica Do Brasil Ltda, in Brazil. The new entity operates within the pharmaceutical sector and is established to manufacture, promote, sell, and distribute pharmaceutical and related products in Brazil. The newly incorporated entity has not commenced business operations yet. The setup falls under the automatic route requiring prior approval from the Reserve Bank of India, with promoters having no direct interest in the entity.
Audio Recording of the Webinar held on September 29, 2026
Intimation · 30 Sept 2026, 12:34 am
Granules India Uploads Audio Recording of Investor Webinar Granules India Limited announced that pursuant to Regulation 46 of SEBI LODR Regulations, 2015, the audio recording of its investor webinar held on 29th Sep'26 has been made available on the company's official website.
Intimation of Schedule of Webinar
Intimation · 27 Sept 2026, 1:41 am
Granules India Outlines Business Transformation and High-Value Growth Drivers Granules India scheduled a webinar on 29th Sep'26 with IIFL Capital to discuss its strategic transition beyond legacy generics. Formulations now generate ~75% of revenue, with legacy-5 portfolio dependence dropping from ~85% in FY23 to <50% in FY26. Future growth centers on controlled substances, complex formulations, injectables, oncology (with potential 180-day exclusivities from FY28), US FTF/Para IV opportunities, and its Senn-backed peptide CDMO platform targeting a USD 100m revenue opportunity over 4–5 years to drive margin expansion.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Uma Devi Chigurupati
Acquisition/ Disposal of Shares · 25 Sept 2026, 11:21 pm
Promoter Uma Devi Chigurupati Acquires 9.12% Stake in Granules India Promoter group member Uma Devi Chigurupati acquired 2,48,80,342 equity shares of Granules India Limited, representing a 9.12% stake, via the open market on 16th Sep'26. Following this transaction, her holding increased from 92,40,761 shares (3.81% voting capital, 12.51% diluted basis) to 3,41,21,103 shares, representing 12.51% of both total voting and diluted share capital. The company’s total voting capital post-acquisition stands at Rs. 27.28 crore (24.28 crore shares), with total diluted capital at Rs. 27.28 crore (27.28 crore shares).
Intimation of Schedule of the Analyst/Investor Meeting
Intimation · 23 Sept 2026, 8:01 pm
Granules India Schedules Analyst and Investor Meeting in New Delhi Granules India Limited announced that its management will meet analysts, investors, and funds on 28th Sep'26 in New Delhi, pursuant to SEBI Listing Regulations. The meeting schedule remains tentative and subject to change. The company confirmed that no unpublished price-sensitive information will be shared during these interactions.
Allotment of equity shares upon conversion of warrants
Others (Uncategorized) · 16 Sept 2026, 11:09 pm
Granules India Allots 2.50 Crore Shares to Promoter Group via Warrant Conversion Granules India approved the allotment of 2,49,82,906 equity shares (face value Re 1) at Rs 585 per share to promoter group entities upon warrant conversion, receiving Rs 1,461.50 crore in total consideration. Consequently, the company's paid-up equity share capital expanded from Rs 24.78 crore (24.78 crore shares) to Rs 27.28 crore (27.28 crore shares), with Ms. Chigurupati Uma Devi's holding increasing from 3.73% to 12.51%. Following this preferential allotment, 17,094 warrants issued to non-promoter investors remain outstanding for conversion.
Update
Others (Uncategorized) · 16 Sept 2026, 1:12 am
Granules India Receives ₹1,093 Crore Warrant Subscription, Turning Net Cash Surplus Granules India received the balance 75% subscription amount of ₹1,093 crore from its Promoter group on 15th Sep'26. Consequently, 2,49,14,530 warrants are fully paid and eligible for conversion into equity shares. Following this capital infusion, the company achieves a consolidated net cash surplus position. This strengthened balance sheet enhances strategic flexibility, enabling Granules India to expedite its preferential issue objectives and deploy growth capital ahead of originally envisaged timelines while maintaining financial discipline.